INVESTORS.

Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker

NASDAQRGLS

Latest Quarter.

See all Quarterly Results

Press Releases.

Investor Alerts

October 08, 2024

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

August 28, 2024

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

August 08, 2024

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1...

More press releases

Events.

H.C. Wainwright 26th Annual Global Investment Conference

Monday, September 9, 2024

10:00am EDT

Wells Fargo Healthcare Conference

Wednesday, September 4, 2024

2:15pm EDT

Canaccord Genuity 44th Annual Growth Conference

Tuesday, August 13, 2024

8:30am EDT

More events